OLMA · Why this verdict
Why Olema Pharmaceuticals (OLMA) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Olema Pharmaceuticals is a cash-burning clinical-stage biotech trading near its 52-week low with an RSI of 20, short interest of 17%, and a put/call ratio of 3.40, yet analysts maintain extremely bullish price targets implying over 300% upside, reflecting high binary risk around pipeline milestones.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The raw analyst target of $40.70 against a current price of $9.88 (a 4.1x ratio) was flagged as implausible and rejected by the pipeline, with the take-profit falling back to technical resistance at $14, indicating that even the technical upside case requires confirmation of positive clinical progress. Warnings | Stock reaches the $14 technical resistance level within 12 months, representing 42% upside from current levels based on the fallback technical target. | →Stable |
| CounterAnalyst targets for clinical-stage biotechs routinely reflect probability-weighted outcomes of pipeline success and can appear extreme relative to current price — the rejection of the target as implausible may itself be too conservative. | ||
Olema Pharmaceuticals generates no revenue and has negative free cash flow, placing the company entirely dependent on external financing to fund clinical development, which creates high dilution risk for current shareholders and business continuity risk if capital markets tighten. Quality breakdown | Cash runway extends to at least 18 months based on disclosed financial reporting, providing adequate buffer to reach key clinical readouts. | →Stable |
| CounterClinical-stage biotechs routinely operate at a loss and are valued on the probability-weighted potential of their drug pipeline rather than current earnings, and analysts projecting over 300% upside suggests meaningful pipeline optionality exists. | ||
Short interest of 17% and a put/call ratio of 3.40 — one of the most bearish options configurations in the dataset — indicate that sophisticated market participants are positioning strongly against Olema, likely in anticipation of negative clinical data or financing-related dilution. Key risks | Short interest falls below 10% and put/call ratio falls below 1.5 within 6 months following positive clinical announcements that reduce binary risk. | →Stable |
| CounterHigh short interest in small-cap biotechs is often driven by hedging activity rather than conviction shorts, and a large short base can amplify upside moves if clinical data surprises positively. | ||
The RSI of 20 and a 52-week position at the very bottom of the range indicate the stock is in a capitulation phase, and the support resistance score of 9.2 suggests the stock is near technically significant support levels where a reversal would be expected if the fundamental story remains intact. Momentum breakdown | Stock price rises above $12 within 3 months as oversold technical conditions attract speculative buying and short covering. | →Stable |
| CounterAn RSI of 20 in a small-cap biotech with falling on-balance volume and a falling knife setup classification can remain extremely oversold for months if negative news continues, making technical support levels unreliable. | ||
The raw analyst target of $40.70 against a current price of $9.88 (a 4.1x ratio) was flagged as implausible and rejected by the pipeline, with the take-profit falling back to technical resistance at $14, indicating that even the technical upside case requires confirmation of positive clinical progress.
→StableWarnings
- Expectation
- Stock reaches the $14 technical resistance level within 12 months, representing 42% upside from current levels based on the fallback technical target.
CounterAnalyst targets for clinical-stage biotechs routinely reflect probability-weighted outcomes of pipeline success and can appear extreme relative to current price — the rejection of the target as implausible may itself be too conservative.
Olema Pharmaceuticals generates no revenue and has negative free cash flow, placing the company entirely dependent on external financing to fund clinical development, which creates high dilution risk for current shareholders and business continuity risk if capital markets tighten.
→StableQuality breakdown
- Expectation
- Cash runway extends to at least 18 months based on disclosed financial reporting, providing adequate buffer to reach key clinical readouts.
CounterClinical-stage biotechs routinely operate at a loss and are valued on the probability-weighted potential of their drug pipeline rather than current earnings, and analysts projecting over 300% upside suggests meaningful pipeline optionality exists.
Short interest of 17% and a put/call ratio of 3.40 — one of the most bearish options configurations in the dataset — indicate that sophisticated market participants are positioning strongly against Olema, likely in anticipation of negative clinical data or financing-related dilution.
→StableKey risks
- Expectation
- Short interest falls below 10% and put/call ratio falls below 1.5 within 6 months following positive clinical announcements that reduce binary risk.
CounterHigh short interest in small-cap biotechs is often driven by hedging activity rather than conviction shorts, and a large short base can amplify upside moves if clinical data surprises positively.
The RSI of 20 and a 52-week position at the very bottom of the range indicate the stock is in a capitulation phase, and the support resistance score of 9.2 suggests the stock is near technically significant support levels where a reversal would be expected if the fundamental story remains intact.
→StableMomentum breakdown
- Expectation
- Stock price rises above $12 within 3 months as oversold technical conditions attract speculative buying and short covering.
CounterAn RSI of 20 in a small-cap biotech with falling on-balance volume and a falling knife setup classification can remain extremely oversold for months if negative news continues, making technical support levels unreliable.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 5.5 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+5.7%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 265%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.0 |
| growth rank | 5.0 |
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.0 |
| support resistance | 5.8 |
| 52w position | 0.0 |
Risk (lower is worse)
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 3.3 |
| debt equity | 6.1 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 3.50
- ▸High IV: 149%
Catalyst
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.4 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Market cap $0.92B below $1B minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:47d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 56
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 2.00>1.3, MCap $0.9B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.9 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.9, Momentum at 7.0, and Value at 5.0; the weakest are Quality at 1.2, Risk (lower is worse) at 2.3, and Technical at 3.3. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Olema Pharmaceuticals generates no revenue and has negative free cash flow, placing the company entirely dependent on external financing to fund clinical development, which creates high dilution risk for current shareholders and business continuity risk if capital markets tighten.
Trip ifCash and equivalents fall below 9 months of projected operating expenses, triggering emergency financing risk.
- P2Short interest of 17% and a put/call ratio of 3.40 — one of the most bearish options configurations in the dataset — indicate that sophisticated market participants are positioning strongly against Olema, likely in anticipation of negative clinical data or financing-related dilution.
Trip ifShort interest rises above 22%, indicating bearish positioning is intensifying rather than unwinding.
- P3The RSI of 20 and a 52-week position at the very bottom of the range indicate the stock is in a capitulation phase, and the support resistance score of 9.2 suggests the stock is near technically significant support levels where a reversal would be expected if the fundamental story remains intact.
Trip ifStock price drops below $7, indicating technical support has failed and capitulation selling has resumed.
- P4The raw analyst target of $40.70 against a current price of $9.88 (a 4.1x ratio) was flagged as implausible and rejected by the pipeline, with the take-profit falling back to technical resistance at $14, indicating that even the technical upside case requires confirmation of positive clinical progress.
Trip ifStock price falls below $8 for more than 30 consecutive trading days, suggesting the technical reversal thesis has failed.